Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA)

NCT ID: NCT05631223

Last Updated: 2026-02-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 101 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-03-10
• Study Completion Date: 2026-02-06

Brief Summary

This will be a single-arm interventional study to test the acceptability, feasibility, and effectiveness of structured telemedicine visits to encourage lifestyle changes that will improve quality of life, disease impact, and disease activity in patients with psoriatic arthritis (PsA).

Detailed Description

The proposed trial will be embedded within clinical care. This is a 2-year interventional trial that will enroll patients with active psoriatic arthritis despite stable therapy among three centers (the University of Pennsylvania, University of Utah, and University of Oxford). The intervention employs PsOWellTM, a program that trains clinicians to utilize motivational interviewing to help patients set goals and make lifestyle/behavior changes for holistic management of psoriasis.

Conditions

Psoriatic Arthritis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Interventional Telemedicine Arm

Single Arm Intervention

Group Type: EXPERIMENTAL

Telemedicine

Intervention Type: BEHAVIORAL

The intervention will consist of two structured telemedicine visits delivered between two routine office visits and conducted by providers (nurse practitioners and clinical nurse specialists).

Interventions

Telemedicine

The intervention will consist of two structured telemedicine visits delivered between two routine office visits and conducted by providers (nurse practitioners and clinical nurse specialists).

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Population: Patients with Psoriatic Arthritis

• Age 18-89.
• Active symptoms of PsA as defined by a PsA Impact of Disease (PsAID) questionnaire score >4 (range 0-10, 4 is the patient acceptable symptom state) or a patient global assessment of greater than 4 (scale 0-10).
• Patients should be stable on therapy (i.e., not planning to switch therapy at the current visit).
• Meet CASPAR criteria.
• Provision of signed and dated informed consent form.
• Willingness to comply with all study procedures and availability for duration of the study.
• Has access to a mobile phone or other mobile device.

Exclusion Criteria

• Inability to provide informed consent.
• Plan to change systemic treatment for psoriasis or PsA in the next 4-8 weeks.
• PsAID score ≤4

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 89 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Pennsylvania

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alexis Ogdie-Beatty, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pennsylvania

Locations

University Of Pennsylvania

Philadelphia, Pennsylvania, United States

University of Utah

Salt Lake City, Utah, United States

Countries

United States

Other Identifiers

851058

Identifier Type: -

Identifier Source: org_study_id